Published “Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial” in The Lancet — cited 4,780 times.
- #crossref
- #research
- #work
Published “Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial” in The Lancet — cited 4,780 times.
Captured 2026-08-24 from Crossref. The archived copy is preserved so this citation survives link rot.